Abstract
Objective: To investigate patient predictors of response to treatment of Major Depressive Episode (MDE) in Alzheimer's disease (AD). Methods: Forty-four outpatients with AD and MDE were randomized to receive either sertraline or placebo in a 12-week placebo-controlled, flexible-dose clinical trial after a one week single-blind placebo phase. All participants were evaluated for depression at entry using the 21-item Hamilton Depression Rating Scale (HDRS) and the Cornell Scale for Depression in Dementia (CSDD). All subjects completed baseline neuropsychological testing. Caregiver burden and depression were also measured. The forty-two subjects who completed at least one post-enrollment follow-up visit were included in the analysis. Results: No baseline demographic, mood, neuropsychiatric, neuropsychological, or caregiver variable was a statistically significant predictor of response to treatment. There were trends for African-American patients (p = 0.07) and those with milder baseline agitation/aggression (p = 0.08) to respond better. Conclusion: No baseline characteristic assessed clearly predicts response to treatment of MDE in AD. A diverse population of depressed AD patients may thus respond similarly to the same treatment.
Original language | English (US) |
---|---|
Pages (from-to) | 144-150 |
Number of pages | 7 |
Journal | International journal of geriatric psychiatry |
Volume | 19 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2004 |
Keywords
- Alzheimer
- Depression
- Sertraline
- Treatment
ASJC Scopus subject areas
- Geriatrics and Gerontology
- Psychiatry and Mental health